Pizzato, Massimo
 Distribuzione geografica
Continente #
NA - Nord America 2.886
EU - Europa 445
AS - Asia 88
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 2
Totale 3.428
Nazione #
US - Stati Uniti d'America 2.885
IT - Italia 172
UA - Ucraina 93
FI - Finlandia 54
CN - Cina 49
SE - Svezia 45
GB - Regno Unito 39
VN - Vietnam 20
DE - Germania 18
TR - Turchia 7
BG - Bulgaria 5
JO - Giordania 5
FR - Francia 4
RU - Federazione Russa 4
SG - Singapore 4
ZA - Sudafrica 3
EU - Europa 2
IN - India 2
SI - Slovenia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BE - Belgio 1
BY - Bielorussia 1
CA - Canada 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EC - Ecuador 1
ES - Italia 1
GR - Grecia 1
LV - Lettonia 1
MU - Mauritius 1
NO - Norvegia 1
Totale 3.428
Città #
Fairfield 508
Chandler 281
Ashburn 260
Woodbridge 249
Seattle 224
Jacksonville 219
Wilmington 188
Cambridge 176
Houston 159
Ann Arbor 96
Princeton 84
San Mateo 81
Trento 71
New York 38
Beijing 28
Como 26
San Diego 23
Dearborn 20
Helsinki 19
London 14
Dong Ket 12
San Paolo di Civitate 9
Verona 9
Rome 8
Izmir 7
Los Angeles 6
Turin 6
Washington 6
Boardman 5
Bremen 5
Fremont 5
Sofia 5
Brugherio 4
Düsseldorf 4
Guangzhou 4
Jinan 4
Riva Del Garda 4
Volargne 4
Hefei 3
Irvine 3
Islington 3
Johannesburg 3
Kilburn 3
Prescot 3
Aberdeen 2
Altamura 2
Busto Arsizio 2
Lagundo 2
Lyon 2
Milan 2
Munich 2
Nanjing 2
Napoli 2
Norwalk 2
Tolmin 2
Villa Lagarina 2
Arnsberg 1
Baku 1
Baotou 1
Brno 1
Changsha 1
Chengdu 1
Chicago 1
Cupertino 1
Des Moines 1
Ferrara di Monte Baldo 1
Frederiksberg 1
Hebei 1
La Canada Flintridge 1
Lappeenranta 1
Las Vegas 1
Lawrence 1
Minsk 1
Moscow 1
Mountain View 1
New Bedfont 1
Nuremberg 1
Olcenengo 1
Oslo 1
Padova 1
Phoenix 1
Piraeus 1
Quito 1
Redmond 1
Riga 1
San Francisco 1
Scuola 1
Shanghai 1
Southwark 1
Toronto 1
Valladolid 1
Villa 1
Wuhan 1
Xian 1
Totale 2.951
Nome #
SERINC5 as a new restriction factor for human immunodeficiency virus and murine leukemia virus 139
SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins 128
The antagonism of HIV Nef to SERINC5 particle infectivity restriction involves the counteraction of virion-associated pools of the restriction factor 124
The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild 110
HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation 110
Retroviral factors promoting infectivity. 108
Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration 102
A bipartite structural organization defines the SERINC family of HIV-1 restriction factors 102
The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles 96
Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. 93
S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3 92
The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists 89
Galanin pathogenic mutations in temporal lobe epilepsy 86
Insertion of targeting domains into the envelope glycoprotein of Moloney murine leukemia virus (MoMLV)-based vectors modulates the route of mCAT-1-mediated viral entry. 85
Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. 85
Gene Therapy of Glioblastoma Multiforme with a Bicistronic Retroviral Vector Expressing Human IL-2 and HSV-tK. 80
Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. 80
Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles. 78
Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. 77
Effect of differential growth conditions on the dTTP pool size in herpes simplex virus-infected Vero cells. 77
A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. 76
Effect of High-Energy Milling on the Dissolution of Anti-HIV Drug Efavirenz in Different Solvents 75
Progress with retroviral gene vectors. 73
Mechanical activation of Efavirenz: the effects on the dissolution and inhibitory behavior 73
Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors. 72
TRIM5 is an innate immune sensor for the retrovirus capsid lattice. 72
Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. 70
The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α. 69
Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. 68
Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75. 67
Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5 66
Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. 65
MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. 64
Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. 63
Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. 61
Determination of HPRT mutant frequency and molecular analysis of T-lymphocyte mutants derived from coke-oven workers. 60
Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. 58
The activity of Nef on HIV-1 infectivity. 56
Centriolar distal appendages activate the centrosome-PIDDosome-p53 signalling axis via ANKRD26 56
SARS-CoV-2 and the Host Cell: A Tale of Interactions 46
A Community Study of SARS-CoV-2 Detection by RT-PCR in Saliva: A Reliable and Effective Method 46
Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping. 45
Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. 39
Retrovirus vectors. 36
Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve 23
Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity 16
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity 13
The impact of infection risk communication format on tourism travel intentions during COVID-19 13
Viral particles imaging through evanescent wave scattering in a total internal reflection laser microscope 12
SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals 12
Host Restriction Factors Modulating HIV Latency and Replication in Macrophages 12
Prospective epidemiological, molecular, and genetic characterization of a novel coronavirus disease in the Val Venosta/Vinschgau: the CHRIS COVID-19 study protocol 11
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer 10
Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals 10
Influence of Different Glycoproteins and of the Virion Core on SERINC5 Antiviral Activity 9
Totale 3.558
Categoria #
all - tutte 16.758
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 272
Totale 17.030


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019319 0 0 0 0 0 0 0 0 0 0 186 133
2019/2020902 62 42 57 103 105 68 116 94 117 46 35 57
2020/2021726 9 69 30 96 102 44 48 56 46 74 99 53
2021/2022481 22 32 8 20 12 31 7 106 48 49 59 87
2022/2023607 63 68 6 69 52 87 9 54 113 35 31 20
2023/2024258 20 20 18 20 34 84 21 22 5 13 1 0
Totale 3.558